Noah Nasser is Serimmune’s chief executive officer. With more than twenty-five years of experience in biotechnology, Noah brings a broad background and experience in the development and commercialization of novel technology to advance human health. Noah joins Serimmune from San Diego biotechnology company, Human Longevity, Inc., a direct-to-consumer health screening organization combining proprietary imaging and genetic technologies, where he was chief commercial officer. Prior to Human Longevity, Noah was chief commercial officer at Counsyl, a market leading genetic testing laboratory focused on women’s health applications including non-invasive prenatal screening, expanded carrier testing and hereditary cancer screening. Noah led Counsyl’s commercial team through its acquisition in 2018 by Myriad Genetics, Inc. He previously held senior leadership positions at San Diego-based biotechnology company AltheaDx, and San Carlos-based Verinata Health, a leader in non-invasive prenatal screening (NIPS), where he led his team through the company’s acquisition by Illumina in 2013. Noah is an Executive in Residence at the University of Utah, Center for Technology and Commercialization and holds a B.S. in Molecular Biology from University of California, San Diego.

John Shon is the Chief Technology Officer of Serimmune where he leads the development of informatics software and algorithms for the company’s platforms. Dr. Shon was most recently Vice President of Bioinformatics and Data Sciences at Illumina, where he led teams of bioinformatics scientists in developing algorithms and methods for Illumina NGS instruments, assays and informatics, with a focus on interpreting whole genomes for population-scale collaborations in rare disease and cancer. Prior to Illumina, Dr. Shon spent more than a decade in key leadership roles at pharmaceutical companies. He was Vice President of Informatics, Research IT and External Innovation at Janssen Pharmaceuticals, where he built data science teams to support R&D, clinical development and diagnostics. At Roche, Dr. Shon led informatics groups in translational research for target discovery, biomarker selection, drug safety and personalized healthcare. He earned his A.B. in Biochemistry from Harvard and an M.D. from Stanford. He completed his residency in Internal Medicine at the University of Chicago and his postdoc at Stanford University School of Medicine, where he also earned an M.S. in Medical Information Sciences.

Steve Kujawa is Vice President of Business Development at Serimmune, leading the company’s immune intelligence partnerships with top pharmaceutical and biotechnology companies. Prior to joining Serimmune, Mr. Kujawa was Senior Director of Market Strategy and Business Development for Pacific Biosciences, and served as Director of Business Development for Incyte Genomics. Earlier in his career, he served as a Director at Burrill & Company, a global financial services firm focused on the life sciences industry, and manager of the medical device group at Frost & Sullivan. Mr. Kujawa holds an A.B. in Biology from Princeton and an MBA from Santa Clara University.